# US 2023/0406915 A1 · Anti-dkk2 antibody, composition containing anti-dkk2 antibody, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406915 A1
- Document ID: US20230406915A1
- Status: Published application
- Kind: A1
- Application number: 18/255,567
- Filed: 2021-11-16
- Published: 2023-12-21
- Earliest claimed: 2020-12-02
- Assignees: Hjb (Hangzhou) Co., Ltd.)
- Applicants: Hjb (Hangzhou) Co., Ltd.)
- Inventors: Dayou Liu; Christopher Hwang
- Web page: https://patentgrep.com/patent/US20230406915A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to a humanized and CMC properties-improved anti-DKK2 antibody, a composition containing the antibody, and a method for treating diseases using the antibody or the composition.

## Claims

### Claim 1

An antibody specifically binding to a human DKK2 protein, wherein the antibody comprises a heavy chain variable region comprising complementarity-determining regions CDRH1, CDRH2, and CDRH3, and a light chain variable region comprising complementarity-determining regions CDRL1, CDRL2, and CDRL3, wherein:
(a) CDRH1 has an amino acid sequence as shown in SEQ ID NO: 1;
(b) CDRH2 has an amino acid sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 3;
(c) CDRH3 has an amino acid sequence as shown in SEQ ID NO: 4;
(d) CDRL1 has an amino acid sequence as shown in SEQ ID NO: 5;
(e) CDRL2 has an amino acid sequence as shown in SEQ ID NO: 6; and
(f) CDRL3 has an amino acid sequence as shown in SEQ ID NO: 7.

### Claim 2 (depends on 1)

The antibody according to claim 1, wherein the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 10 or SEQ ID NO: 14.

### Claim 3 (depends on 2)

The antibody according to claim 2, wherein the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 12.

### Claim 4 (depends on 3)

The antibody according to claim 3, wherein the heavy chain of the antibody comprises an amino acid sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 15, or an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to the amino acid sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 15.

### Claim 5 (depends on 4)

The antibody according to claim 4, wherein the light chain of the antibody comprises an amino acid sequence as shown in SEQ ID NO: 9 or SEQ ID NO: 13, or an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to the amino acid sequence as shown in SEQ ID NO: 9 or SEQ ID NO: 13.

### Claim 6 (depends on 1)

The antibody according to claim 1,
wherein the heavy chain variable region and/or the light chain variable region are a part of a single-chain variable fragment scFv, an F(ab′)2 fragment, an Fab or Fab′ fragment, a bivalent antibody, a trivalent antibody, a tetravalent antibody or a monoclonal antibody.

### Claim 7 (depends on 1)

A pharmaceutical composition, comprising the antibody according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A DNA molecule, encoding the heavy chain and/or light chain of the antibody according to claim 1.

### Claim 9 (depends on 1)

A method for treating cancer in a subject in need thereof or for stimulating or enhancing an immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of the antibody according to claim 1.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the antibody is administered to the subject at a dose of 0.01-50 mg/kg/day with an interval between 1-14 days.

### Claim 11 (depends on 1)

Use of the antibody according to claim 1 in the manufacture of a drug for treating cancer in a subject in need thereof or for stimulating or enhancing an immune response in a subject in need thereof.
